Stefano Portolano MD
About
Stefano Portolano MD is from Basel, Basel, Switzerland. Stefano is currently Chief Executive Officer at AZAFAROS B.V., located in Basel, Switzerland. In Stefano's previous role as a Regional Head, Europe at Ultragenyx Pharmaceutical Inc., Stefano worked in Basel Area, Switzerland until May 2021. Prior to joining Ultragenyx Pharmaceutical Inc., Stefano was a Vice President, Strategy & Commercial Operations at Celgene and held the position of Vice President, Strategy & Commercial Operations at Lausanne Area, Switzerland. Prior to that, Stefano was a Vice President, Hematology Europe at Celgene, based in Switzerland from Apr 2012 to Oct 2014. Stefano started working as Managing Director, General Manager at Celgene in Milan Area, Italy in Jun 2006. From Sep 2010 to Apr 2012, Stefano was Regional General Manager at Celgene, based in Milan Area, Italy. Prior to that, Stefano was a Managing Director, General Manager, Greece at Genzyme, based in Greece from Jan 2005 to Jun 2006. Stefano started working as Vice President, Business Unit Lead, Europe at Genzyme Europe BV in Amsterdam Area, Netherlands in Sep 2002.
Stefano Portolano MD's email is available on Finalscout.com free of charge. This database has a wealth of information on over half a billion business professionals and two hundred million companies.
Stefano Portolano MD's current jobs
Turning hope into disease-modifying therapies for people living with severe rare metabolic disorders
Stefano Portolano MD's past jobs
Reporting to the President, EMEA, responsible for leadership of strategic initiatives, including novel initiatives, real world data efforts, value added services, digital channels. Also responsible for managing commercial operations functions, including training, commercial excellence, project management and congress management, to drive regional commercial execution in alignment with global marketing across all franchises, products and indications.
Reporting to the President EMEA, responsible for: • building and executing the overall product, brand and indication strategy, and implementing a pan-European marketing plan in order to establish and drive the growth, across the whole region, of Celgene’s marketed and new products, as well as future disease indications. • providing key Brand Marketing expertise for the affiliates to provide adequate counselling to each country in line with its specific external & internal situation • leading the European Marketing Teams in: Strategic plan design, tactical implementation/action plans, portfolio management launch, and management pre- and post- marketing activities • providing commercial input into Market Access strategy, to ensure advanced input on health outcomes, clinical trial strategies, outcomes research and market access viability for each of the company’s assets • acting as the strategic channel between Corporate Development and Europe, representing European interests on a longer term perspective including Business Development • member of key EMEA and Global governance committees
General Manager of Celgene Italy affiliate. Completed the start up of the affiliate, bringing it from zero to 140 employees, > € 150 M revenues, making Celgene a leader in hematology in Italy
In addition to the role of General Manager, Italy, responsible for Israel, Greece and Turkey. Management of distributors in these markets and of the affiliate in Turkey.
Establishment and start up of the Greek affiliate (25 employees), taking over business from the distributor and obtaining reimbursement for Genzyme products in the Greek market.
Leading the European Business Unit Rare Diseases. Responsible for the Marketing and Medical Affairs teams, providing leadership to the affiliates for the rare disease franchise (> € 350 M at the time).
Market Access and Medical Affairs support to the US market for the rare diseases franchise. Working closely with the commercial and marketing teams, lead the establishment and on going development of "centers of excellence" for rare disease in the USA. In collaboration with Clinical R&D, development of post marketing clinical studies to support product knowledge and appropriate use. Design and implementation of screening programs for rare diseases.
Pre-launch activities for recombinant human thyroid stimulating hormone (rhTSH, Thyrogen) in thyroid cancer.
Medical Affairs support to international markets
Molecular biology research in human autoimmune diseases of the thyroid
Molecular biology research in human autoimmune diseases of the thyroid